Boston Biotech Biz Raises $150M In Series B Funding Round
Clinical-stage biotechnology company Rapport Therapeutics Inc., advised by Goodwin Procter LLP, on Wednesday announced that it raised $150 million in Series B funding that will help the company advance its clinical...To view the full article, register now.
Already a subscriber? Click here to view full article